摘要 : Abstract Metabolic syndrome (MetS) is a multifactorial disease with medical conditions such as hypertension, diabetes, obesity, dyslipidemia, and insulin resistance. Alpha‐lipoic acid (α‐LA) possesses various pharmacological eff... 展开 Abstract Metabolic syndrome (MetS) is a multifactorial disease with medical conditions such as hypertension, diabetes, obesity, dyslipidemia, and insulin resistance. Alpha‐lipoic acid (α‐LA) possesses various pharmacological effects, including antidiabetic, antiobesity, hypotensive, and hypolipidemia actions. It exhibits reactive oxygen species scavenger properties against oxidation and age‐related inflammation and refines MetS components. Also, α‐LA activates the 5′ adenosine monophosphate‐activated protein kinase and inhibits the NFκb. It can decrease cholesterol biosynthesis, fatty acid β‐oxidation, and vascular stiffness. α‐LA decreases lipogenesis, cholesterol biosynthesis, low‐density lipoprotein and very low‐density lipoprotein levels, and atherosclerosis. Moreover, α‐LA increases insulin secretion, glucose transport, and insulin sensitivity. These changes occur via PI3K/Akt activation. On the other hand, α‐LA treats central obesity by increasing adiponectin levels and mitochondrial biogenesis and can reduce food intake mainly by SIRT1 stimulation. In this review, the most relevant articles have been discussed to determine the effects of α‐LA on different components of MetS with a special focus on different molecular mechanisms behind these effects. This review exhibits the potential properties of α‐LA in managing MetS; however, high‐quality studies are needed to confirm the clinical efficacy of α‐LA. 收起